Heart Attack News and Research

RSS

Genetic test helps reduce hospitalization rates for heart patients on warfarin

Hospitalization rates for heart patients taking warfarin, the world's most-prescribed blood thinner, dropped by approximately 30 percent when genetic information was available to doctors prescribing the drug, researchers from Medco Health Solutions, Inc.-- in association with the Medco Research Institute™ -- and Mayo Clinic announced today.

17 Mar 2010

Pathway Genomics' personal Genetic Health Report now available

Pathway Genomics Inc., a U.S. based genetic testing company, announced the immediate availability of its personal Genetic Health Report. This customized and innovative personal genetic health report contains information on more than 70 health conditions, including pharmacogenetics (prescription medication response), propensity for complex disease, and carrier status (pre-pregnancy health).

17 Mar 2010

New clinical guidelines: Early diagnosis and treatment of TAD can save lives

When actor John Ritter died suddenly in 2003 from a tear in his thoracic aorta-the large artery that carries blood from the heart to the rest of the body-that tragedy brought attention to a rare but deadly condition that takes the lives of an estimated 10,000 Americans each year.

17 Mar 2010

Obese patients face lower risk of sudden cardiac death compared to non-obese patients

Obesity has long been identified as a risk factor for cardiovascular disease and heart failure. But, a new study conducted by researchers at the University of Rochester Medical Center found that being skinny confers no advantage when it comes to the risk of dying suddenly from cardiac causes.

17 Mar 2010

Glenmark Generics, Konec ordered to stop marketing unapproved nitroglycerin tablets

The U.S. Food and Drug Administration today ordered Glenmark Generics of Mahwah, N.J., and Konec Inc. of Tucson, Ariz., to stop marketing unapproved nitroglycerin tablets. The tablets are placed under the tongue to relieve chest pain or to stop a heart attack and are marketed in 0.3 mg, 0.4 mg, and 0.6 mg dosages.

17 Mar 2010

Unapproved nitroglycerin tablets: FDA orders Glenmark Generics and Konec to stop marketing

17 Mar 2010

Lipitor 80 mg may help reduce risk of major cardiovascular events in high-risk patients

Lipitor® (atorvastatin calcium) 80 mg was associated with a significantly reduced risk of major cardiovascular events compared with Lipitor 10 mg among patients with both coronary heart disease (CHD) and chronic kidney disease (CKD) who were obese or had metabolic syndrome. These data, from two sub-analyses of the Treating to New Targets (TNT) trial that were designed and completed following the completion of TNT, were presented today at the 59th Annual Scientific Session of the American College of Cardiology (ACC) in Atlanta, Ga.

16 Mar 2010

Study suggests HuR gene plays a critical role in inducing cells' inflammatory response

To understand the role of inflammation in cardiovascular and other diseases, it is essential to identify and characterize genes that induce an inflammatory response in the body -- and the genes that regulate them.

16 Mar 2010

Vitamin D supplements might do more harm than good for African-American patients

Vitamin D is quickly becoming the "go-to" remedy for treating a wide range of illnesses, from osteoporosis to atherosclerosis. However, new evidence from a Wake Forest University School of Medicine study suggests that supplementing vitamin D in those with low levels may have different effects based on patient race and, in black individuals, the supplement could actually do harm.

16 Mar 2010

Concurrent use of proton-pump inhibitor and clopidogrel does not elevate cardiovascular risk

Heart patients who took a stomach acid-suppressing proton-pump inhibitor along with clopidogrel - a drug that prevents blood clots - were only half as likely to be hospitalized for upper digestive tract bleeding than those who used clopidogrel alone, according to a new study supported by HHS' Agency for Healthcare Research and Quality and the National Heart, Lung, and Blood Institute at the National Institutes of Health.

16 Mar 2010

New cerebral protection device prevents stroke during treatment to clear blocked carotid arteries

An important interventional radiology advancement-the use of a new cerebral protection device in combination with FDA-approved carotid stents in high-surgical-risk patients-provides a minimally invasive, safe and effective way to prevent stroke from occurring during treatment to clear blocked carotid arteries, according to research released at the Society of Interventional Radiology's 35th Annual Scientific Meeting in Tampa, Fla.

16 Mar 2010

Drug-eluting stents offer new hope to patients with critical limb ischemia

In the United States, more than 100,000 amputations are performed each year on individuals with critical limb ischemia, the most severe form of peripheral arterial disease (PAD). The number one priority in treating these patients is to re-establish blood flow to avoid limb amputation.

16 Mar 2010

Boston Scientific announces results from HORIZONS AMI trial assessing Express bare-metal stent

Boston Scientific Corporation today announced results from an analysis of one-year subset data from the HORIZONS AMI trial assessing the impact of diabetes on clinical and angiographic outcomes in heart attack patients treated with the TAXUS® Express2™ Paclitaxel-Eluting Stent System or the Express® bare-metal stent.

16 Mar 2010

CYPHER Sirolimus-eluting Coronary Stent provides better outcome compared to Medtronic’s Endeavor Stent

Investigators reported the long-term follow-up of the largest randomized comparison between the CYPHER® Sirolimus-eluting Coronary Stent and Medtronic’s Endeavor® Stent highlighting significant and sustained clinical differences. These important findings were presented at the American College of Cardiology annual meeting, (ACC 2010) in Atlanta and published on-line in the prestigious journal The Lancet.

16 Mar 2010

High ABI may indicate risk for future heart attacks

The prevalence of abnormal ankle-brachial index (ABI) test results among individuals tested for peripheral arterial disease (PAD)—and who are not considered at high risk of a coronary heart event by Framingham-based risk factors—is high and provides another way to identify those who may be at risk for future heart attacks, say researchers at the Society of Interventional Radiology's 35th Annual Scientific Meeting in Tampa, Fla.

15 Mar 2010

Program to obtain transplant organs from ER patients creates controversy

The Washington Post: "In the hope of expanding a controversial form of organ donation into emergency rooms around the United States, a federally funded project has begun trying to obtain kidneys, livers and possibly other body parts from car-accident victims, heart-attack fatalities and other urgent-care patients.

15 Mar 2010

St. Jude Medical announces updates to PressureWire platform at ACC and SIR annual meetings

St. Jude Medical, Inc., a global medical device company, announced several updates to its PressureWire™ platform, including a new marketing agreement with Siemens Medical Solutions USA, for the wireless PressureWire™ Aeris and the availability of the next-generation of PressureWire™ Certus technology, at the American College of Cardiology and the Society of Interventional Radiology annual meetings.

15 Mar 2010

Valsartan delays progression to type 2 diabetes in IGT patients: NAVIGATOR study

Results from a landmark study involving more than 9,000 people showed that the high blood pressure medicine valsartan delayed progression to type 2 diabetes in patients with cardiovascular disease or risk factors and impaired glucose tolerance (IGT), a common pre-diabetic condition.

15 Mar 2010

First Edition: March 15, 2010

Today's headlines drive home one key point -- for the Democrats' health bill, it's all about gathering the votes.

15 Mar 2010

Mitral regurgitation: MitraClip safe, effective alternative option to open heart surgery

NorthShore University HealthSystem (NorthShore) interventional cardiologist, Ted Feldman, MD, presented data today at the American College of Cardiology annual scientific sessions from the EVEREST II trial (Endovascular Valve Edge-to-Edge REpair STudy) demonstrating the MitraClip, a novel, first-in-class catheter-based device, is a safe and effective alternative to open heart surgery for select patients with mitral regurgitation.

15 Mar 2010

Heart Attack News and Research

Genetic test helps reduce hospitalization rates for heart patients on warfarin

Pathway Genomics' personal Genetic Health Report now available

New clinical guidelines: Early diagnosis and treatment of TAD can save lives

Obese patients face lower risk of sudden cardiac death compared to non-obese patients

Glenmark Generics, Konec ordered to stop marketing unapproved nitroglycerin tablets

Unapproved nitroglycerin tablets: FDA orders Glenmark Generics and Konec to stop marketing

Lipitor 80 mg may help reduce risk of major cardiovascular events in high-risk patients

Study suggests HuR gene plays a critical role in inducing cells' inflammatory response

Vitamin D supplements might do more harm than good for African-American patients

Concurrent use of proton-pump inhibitor and clopidogrel does not elevate cardiovascular risk

New cerebral protection device prevents stroke during treatment to clear blocked carotid arteries

Drug-eluting stents offer new hope to patients with critical limb ischemia

Boston Scientific announces results from HORIZONS AMI trial assessing Express bare-metal stent

CYPHER Sirolimus-eluting Coronary Stent provides better outcome compared to Medtronic’s Endeavor Stent

High ABI may indicate risk for future heart attacks

Program to obtain transplant organs from ER patients creates controversy

St. Jude Medical announces updates to PressureWire platform at ACC and SIR annual meetings

Valsartan delays progression to type 2 diabetes in IGT patients: NAVIGATOR study

First Edition: March 15, 2010

Mitral regurgitation: MitraClip safe, effective alternative option to open heart surgery

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News